Simvastatin increases Prolyl-4-Hydroxylase α1 expression in atherosclerotic plaque and ox-LDL-stimulated human aortic smooth muscle cells via p38 MAPK and ERK1/2 signaling

Journal of Molecular and Cellular Cardiology

Volumn 65, Issue , 2013, Pages 43-50

  Zhang, Kai ^a   Meng, Xiao ^a   Kong, Jing ^a   Liu, Fang Fang ^a   Yang, Jian Min ^a   Gao, Fei ^a   Zhang, Yun ^a   Zhang, Cheng ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Atherosclerosis; Mitogen activated protein kinases; Oxidized low density lipoprotein; Prolyl 4 Hydroxylase 1; Simvastatin

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; APOLIPOPROTEIN E; COLLAGEN TYPE 1; COLLAGEN TYPE 3; METHYLCELLULOSE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; OXIDIZED LOW DENSITY LIPOPROTEIN; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; PROLYL 4 HYDROXYLASE ALPHA1; SIMVASTATIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA MEDIA; ARTICLE; ATHEROSCLEROTIC PLAQUE; CAROTID ATHEROSCLEROSIS; CELL STIMULATION; COLLAGEN SYNTHESIS; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENE SILENCING; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER;

MUS;

ATHEROSCLEROSIS; MITOGEN-ACTIVATED PROTEIN KINASES; OXIDIZED LOW DENSITY LIPOPROTEIN; PROLYL-4-HYDROXYLASE Α1; SIMVASTATIN;

ANIMALS; AORTA; BODY WEIGHT; COLLAGEN; DOWN-REGULATION; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; LIPIDS; LIPOPROTEINS, LDL; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED C57BL; MYOCYTES, SMOOTH MUSCLE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PLAQUE, ATHEROSCLEROTIC; PROLYL HYDROXYLASES; SIMVASTATIN; TIME FACTORS;

EID: 84885513714     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2013.09.010     Document Type: Article

References (25)

1. Virmani R., Burke A.P., Farb A., Kolodgie F.D. Pathology of the vulnerable plaque. J Am Coll Cardiol 2006, 47:C13-C18.
2. Shah P.K. Mechanisms of plaque vulnerability and rupture. J Am Coll Cardiol 2003, 41:15S-22S.
3. Libby P. Molecular bases of the acute coronary syndromes. Circulation 1995, 91:2844-2850.
4. Kivirikko K.I., Helaakoski T., Tasanen K., Vuori K., Myllyla R., Parkkonen T., et al. Molecular biology of prolyl 4-hydroxylase. Ann N Y Acad Sci 1990, 580:132-142.
5. Kivirikko K.I., Pihlajaniemi T. Collagen hydroxylases and the protein disulfide isomerase subunit of prolyl 4-hydroxylases. Adv Enzymol Relat Areas Mol Biol 1998, 72:325-398.
6. Chen L., Shen Y.H., Wang X., Wang J., Gan Y., Chen N., et al. Human prolyl-4-hydroxylase alpha(I) transcription is mediated by upstream stimulatory factors. J Biol Chem 2006, 281:10849-10855.
7. Zhang C., Zhang M.X., Shen Y.H., Burks J.K., Zhang Y., Wang J., et al. TNF-alpha suppresses prolyl-4-hydroxylase alpha1 expression via the ASK1-JNK-NonO pathway. Arterioscler Thromb Vasc Biol 2007, 27:1760-1767.
8. Li L., Zhang K., Cai X.J., Feng M., Zhang Y., Zhang M. Adiponectin upregulates prolyl-4-hydroxylase alpha1 expression in interleukin 6-stimulated human aortic smooth muscle cells by regulating ERK 1/2 and Sp1. PLoS One 2011, 6:e22819.
9. Chisolm G.M., Steinberg D. The oxidative modification hypothesis of atherogenesis: an overview. Free Radic Biol Med 2000, 28:1815-1826.
10. Werner N., Nickenig G., Laufs U. Pleiotropic effects of HMG-CoA reductase inhibitors. Basic Res Cardiol 2002, 97:105-116.
11. Luan Z., Chase A.J., Newby A.C. Statins inhibit secretion of metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophages. Arterioscler Thromb Vasc Biol 2003, 23:769-775.
12. Cheng C., Noordeloos A.M., Jeney V., Soares M.P., Moll F., Pasterkamp G., et al. Heme oxygenase 1 determines atherosclerotic lesion progression into a vulnerable plaque. Circulation 2009, 119:3017-3027.
13. Ni M., Wang Y., Zhang M., Zhang P.F., Ding S.F., Liu C.X., et al. Atherosclerotic plaque disruption induced by stress and lipopolysaccharide in apolipoprotein E knockout mice. Am J Physiol Heart Circ Physiol 2009, 296:H1598-H1606.
14. Zhang L., Liu Y., Lu X.T., Xu X.S., Zhao Y.X., Ji X.P., et al. Intraplaque injection of Ad5-CMV.p53 aggravates local inflammation and leads to plaque instability in rabbits. J Cell Mol Med 2009, 13:2713-2723.
15. Chen K.C., Wang Y.S., Hu C.Y., Chang W.C., Liao Y.C., Dai C.Y., et al. OxLDL up-regulates microRNA-29b, leading to epigenetic modifications of MMP-2/MMP-9 genes: a novel mechanism for cardiovascular diseases. FASEB J 2011, 25:1718-1728.
16. Muslin A.J. MAPK signalling in cardiovascular health and disease: molecular mechanisms and therapeutic targets. Clin Sci (Lond) 2008, 115:203-218.
17. Li D., Mehta J.L. Antisense to LOX-1 inhibits oxidized LDL-mediated upregulation of monocyte chemoattractant protein-1 and monocyte adhesion to human coronary artery endothelial cells. Circulation 2000, 101:2889-2895.
18. Zhong Y., Liu T., Guo Z. Curcumin inhibits ox-LDL-induced MCP-1 expression by suppressing the p38MAPK and NF-kappaB pathways in rat vascular smooth muscle cells. Inflamm Res 2012, 61:61-67.
19. Maziere C., Trecherel E., Ausseil J., Louandre C., Maziere J.C. Oxidized low density lipoprotein induces cyclin A synthesis. Involvement of ERK, JNK and NFkappaB. Atherosclerosis 2011, 218:308-313.
20. Girotra S., Murarka S., Migrino R.Q. Plaque regression and improved clinical outcomes following statin treatment in atherosclerosis. Panminerva Med 2012, 54:71-81.
21. Antonopoulos A.S., Margaritis M., Lee R., Channon K., Antoniades C. Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials. Curr Pharm Des 2012, 18:1519-1530.
22. Meng X., Zhang K., Li J., Dong M., Yang J., An G., et al. Statins induce the accumulation of regulatory T cells in atherosclerotic plaque. Mol Med 2012, 18:598-605.
23. Qin Y.W., Ye P., He J.Q., Sheng L., Wang L.Y., Du J. Simvastatin inhibited cardiac hypertrophy and fibrosis in apolipoprotein E-deficient mice fed a "Western-style diet" by increasing PPAR alpha and gamma expression and reducing TC, MMP-9, and Cat S levels. Acta Pharmacol Sin 2010, 31:1350-1358.
24. Massaro M., Zampolli A., Scoditti E., Carluccio M.A., Storelli C., Distante A., et al. Statins inhibit cyclooxygenase-2 and matrix metalloproteinase-9 in human endothelial cells: anti-angiogenic actions possibly contributing to plaque stability. Cardiovasc Res 2010, 86:311-320.
25. Fukumoto Y., Libby P., Rabkin E., Hill C.C., Enomoto M., Hirouchi Y., et al. Statins alter smooth muscle cell accumulation and collagen content in established atheroma of watanabe heritable hyperlipidemic rabbits. Circulation 2001, 103:993-999.